Literature DB >> 17714731

Contrasting glycosylation profiles between Fab and Fc of a human IgG protein studied by electrospray ionization mass spectrometry.

Yusuke Mimura1, Peter R Ashton, Noriko Takahashi, David J Harvey, Roy Jefferis.   

Abstract

A conserved structural feature of human IgG molecules is the presence of an oligosaccharide moiety within the Fc region at Asn297. In addition, 15-20% of normal polyclonal IgG molecules bear N-linked oligosaccharides in the variable (V) regions of the light (L) and/or heavy (H) chains. Electrospray ionization mass spectrometry (ESI-MS) has been applied to the glycan analysis of two IgG1 myeloma proteins (Wid and Cri) after mild reduction and acidification. Heterogeneous ion peaks were observed for both the H and L chains of Wid in contrast to Cri whose L chain peak was homogeneous. Site-specific deglycosylation of the H and L chains of IgG Wid was achieved under native conditions with peptide-N-glycosidase F and endoglycosidase F2, respectively. The Fc glycoforms differed between the two proteins in that Cri-Fc bears diantennary complex-type glycans that are fully core-fucosylated and partially sialylated while Wid-Fc glycans are non-fucosylated, partially galactosylated and non-sialylated. In contrast to the Fc glycans, the L chain glycans of Wid were shown to be fucosylated, fully galactosylated and sialylated, indicating that the glycosylation machinery of the Wid-producing myeloma cells is intact. Thus, combination of the two endoglycosidases can provide a simple means of glycan analysis of both Fab and Fc by ESI-MS, which may contribute to the development of therapeutic IgG with customized glycan profiles.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17714731     DOI: 10.1016/j.jim.2007.07.014

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  39 in total

Review 1.  The role of sialic acid as a modulator of the anti-inflammatory activity of IgG.

Authors:  Sybille Böhm; Inessa Schwab; Anja Lux; Falk Nimmerjahn
Journal:  Semin Immunopathol       Date:  2012-03-22       Impact factor: 9.623

Review 2.  IgG Fc Glycosylation in Human Immunity.

Authors:  Taia T Wang
Journal:  Curr Top Microbiol Immunol       Date:  2019       Impact factor: 4.291

3.  Comparison of LC and LC/MS methods for quantifying N-glycosylation in recombinant IgGs.

Authors:  Sandipan Sinha; Gary Pipes; Elizabeth M Topp; Pavel V Bondarenko; Michael J Treuheit; Himanshu S Gadgil
Journal:  J Am Soc Mass Spectrom       Date:  2008-07-16       Impact factor: 3.109

4.  Rapid Fc glycosylation analysis of Fc fusions with IdeS and liquid chromatography mass spectrometry.

Authors:  Heather Lynaugh; Huijuan Li; Bing Gong
Journal:  MAbs       Date:  2013-06-20       Impact factor: 5.857

5.  Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab.

Authors:  Carola W N Damen; Weibin Chen; Asish B Chakraborty; Mike van Oosterhout; Jeffrey R Mazzeo; John C Gebler; Jan H M Schellens; Hilde Rosing; Jos H Beijnen
Journal:  J Am Soc Mass Spectrom       Date:  2009-08-07       Impact factor: 3.109

6.  A Method for Comprehensive Glycosite-Mapping and Direct Quantitation of Serum Glycoproteins.

Authors:  Qiuting Hong; L Renee Ruhaak; Carol Stroble; Evan Parker; Jincui Huang; Emanual Maverakis; Carlito B Lebrilla
Journal:  J Proteome Res       Date:  2015-11-09       Impact factor: 4.466

Review 7.  Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity?

Authors:  Michaela Seeling; Christin Brückner; Falk Nimmerjahn
Journal:  Nat Rev Rheumatol       Date:  2017-09-14       Impact factor: 20.543

Review 8.  Analytical and Functional Aspects of Antibody Sialylation.

Authors:  Johannes Stadlmann; Martin Pabst; Friedrich Altmann
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

9.  Asparagine-linked oligosaccharides present on a non-consensus amino acid sequence in the CH1 domain of human antibodies.

Authors:  John F Valliere-Douglass; Paul Kodama; Mirna Mujacic; Lowell J Brady; Wes Wang; Alison Wallace; Boxu Yan; Pranhitha Reddy; Michael J Treuheit; Alain Balland
Journal:  J Biol Chem       Date:  2009-09-18       Impact factor: 5.157

10.  Stabilizing the CH2 Domain of an Antibody by Engineering in an Enhanced Aromatic Sequon.

Authors:  Wentao Chen; Leopold Kong; Stephen Connelly; Julia M Dendle; Yu Liu; Ian A Wilson; Evan T Powers; Jeffery W Kelly
Journal:  ACS Chem Biol       Date:  2016-04-29       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.